MedTrace Logo

A Study of Avoralstat In Participants With Diabetic Macular Edema

NCT07228559 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-05-11

No results posted yet for this study

Summary

The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.

Conditions

  • Diabetic Macular Edema (DME)

Interventions

DRUG

avoralstat

BCX4161 for suprachoroidal injection

Sponsors & Collaborators

  • BioCryst Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-02
Primary Completion
2026-04-17
Completion
2026-04-17
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07228559 on ClinicalTrials.gov